Eisai
$80.969876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$80.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.10 (+0.12%) As of 10:27 AM EDT today
Why Robinhood?
You can buy or sell Eisai and other stocks, options, and ETFs commission-free!
About ESALY
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. Read More The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan. ESALY is listed on the Pink Current market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com). The listed name for ESALY is Eisai Co Ltd American Depositary Shares.
CEO
Employees
10,998
Headquarters
Tokyo, Tokyo
Founded
1936
Market Cap
23.21B
Price-Earnings Ratio
20.13
Dividend Yield
—
Average Volume
4.97K
High Today
$80.96
Low Today
$80.96
Open Price
$80.96
Volume
0.00
52 Week High
$92.54
52 Week Low
$54.00
Collections
ESALY News
Benzinga11h
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 13th Clinical Trials on Alzheimer's Disease Conference
Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120
TOKYO, Oct 28, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that th
Analyst Ratings
30%
of 10 ratings
Buy
30%
Hold
60%
Sell
10%